知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.011 seconds)

    PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF
    3.
    发明申请
    PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF 有权

    公开(公告)号：US20250034253A1

    公开(公告)日：2025-01-30

    申请号：US18264138

    申请日：2023-02-14

    Applicant: Akeso Biopharma, Inc.

    Inventor： Yu XIA ,  Zhongmin WANG ,  Baiyong LI

    IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22

    Abstract: The present invention relates to the field of pharmaceuticals, particularly to an anti-TIGIT antibody, a pharmaceutical composition, and use thereof, and more particularly to use in combination with an anti-PD-1/anti-VEGFA antibody in preventing or treating a tumor. Specifically, the present invention relates to an anti-TIGIT antibody or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising HCDR1-HCDR3 having amino acid sequences set forth in SEQ ID NOs: 3-5, respectively; and the antibody comprises a light chain variable region comprising LCDR1-LCDR3 having amino acid sequences set forth in SEQ ID NOs: 8-10, respectively. The antibody of the present invention can effectively bind to TIGIT and has the potential for use in tumor prevention and treatment.

    ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    9.
    发明申请
    ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF 有权

    公开(公告)号：US20230027029A1

    公开(公告)日：2023-01-26

    申请号：US17779425

    申请日：2020-11-25

    Applicant: AKESO BIOPHARMA, INC.

    Inventor： Peng ZHANG ,  Baiyong LI ,  Yu XIA ,  Zhongmin WANG

    IPC: C07K16/28 ,  C07K16/22 ,  A61K47/68 ,  A61P35/00

    Abstract: Provided are an anti-VEGFA-anti-PD-1 bispecific antibody and a use thereof. Specifically, the anti-VEGFA-anti-PD-1 bispecific antibody comprises: a PD-1-targeted first protein functional region and a VEGFA-targeted second protein functional region. According to an EU numbering system, mutation occurs at two positions of positions 234 and 235 of a heavy chain constant region of the immunoglobulin contained in the bispecific antibody, and after the mutation, an affinity constant of the bispecific antibody with FcγRI, FcγRIIa, FcγRIIIa, and/or C1q is decreased compared to that before the mutation. The bispecific antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 on an organism, and inhibit tumor-induced angiogenesis, and thus has good application prospects.

    ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
    10.
    发明申请
    ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE 有权

    公开(公告)号：US20250042995A1

    公开(公告)日：2025-02-06

    申请号：US18696559

    申请日：2022-09-28

    Applicant: AKESO BIOPHARMA, INC.

    Inventor： Yu XIA ,  Zhongmin WANG ,  Peng ZHANG ,  Baiyong LI

    IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68

    Abstract: The present invention belongs to the field of biomedicine, and relates to an anti-LAG3 antibody, a pharmaceutical composition containing same, and the use thereof. Specifically, the present invention relates to an anti-LAG3 antibody or an antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 9-11, respectively, and the light chain variable region comprises LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 12-14, respectively. The anti-LAG3 antibody of the present invention has superior affinity and specificity, and has good application prospects.

Patent Agency Ranking